Drugs that contain Vosoritide
1. Drug name - VOXZOGO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8198242 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
Jun, 2030
(7 years from now) | |
| CN102481330B | BIOMARIN PHARM | C-Type Natriuretic Peptide Variants |
May, 2030
(7 years from now) | |
| CN102481330A | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| IN201109124P1 | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| IN391651B | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| EP3175863B1 | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| EP3175863A1 | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| EP2432489B1 | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| EP2432489A4 | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| EP2432489A2 | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48267 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
May, 2030
(7 years from now) | |
| US10646550 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(13 years from now) | |
| US9907834 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(13 years from now) | |
Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses
Dosage: POWDER;SUBCUTANEOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 0.4MG/VIAL | POWDER;SUBCUTANEOUS | Prescription |
| 0.56MG/VIAL | POWDER;SUBCUTANEOUS | Prescription |
| 1.2MG/VIAL | POWDER;SUBCUTANEOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.